Quarterly Dinners

Indy Hematology Clinical Rounds®

A quarterly CME education program at Ruth’s Chris Steak House, Indianapolis

Next meeting:

Wednesday, October 22nd, 2025

5:15 - 8:45 PM EDT

Discuss Hematologic Malignancies and Disorders

In pursuant of promoting education in hematologic malignancies and disorders, Dr. Ruemu Birhiray, President and CEO of Indy Hematology Education, Inc, in collaboration with Dr’s. Sumeet Bhatia, David Wilson, Subhash Sharma and Ashwin Vasudevamurthy co- chair “Indy Hematology Clinical Rounds®” a quarterly CME education program.

This program is to create a tumor board forum where management of complex hematological cases can be discussed amongst physicians practicing mainly hematology malignancies and disorders, so that consistency is achieved for better outcomes

Purdue University College of Pharmacy designates this Live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™.

Our Featured Speaker

Swaminathan P. Iyer, MD

University of Texas MD Anderson Cancer Centre Houston, Texas, USA

Department of Lymphoma-Myeloma Division of Cancer Medicine

  • Professor of Medicine

  • Medical Director

Dr. Swaminathan P. Iyer, is a Professor of Medicine in the Department of Lymphoma/Myeloma at University of Texas, MD Anderson. After completing medical training at Bangalore Medical College in India, Dr. Iyer completed his residency in internal medicine at Wayne State University. He completed his fellowship in hematology and oncology at the University of Miami. He is a physician scientist with extensive expertise in clinical studies particularly in Hematological Malignancies such as leukemia and lymphoma, in addition to laboratory interests in developing small molecules, aptamers and drug delivery technologies such as nanoparticles into the clinic, he has led many trials including first-in-man studies, exploration of different doses and schedules of administration and investigational agent combinations, and the examination of biomarkers for patient selection. He was part of pivotal studies that led to the FDA approval of the new anti-CD20 monoclonal antibody Ofatumumab or Arzerra in Chronic Lymphocytic Leukemia. He leads the T cell lymphoma program at MD Anderson. His laboratory interests are in developing aptamers against targets in hematological malignancies.

Case Presentations/Discussion on “Hemophagocytic Lymphohistiocytosis (HLH) and Defining MRD Status in Hematologic Malignancies.”

Product Theater Sponsor

Adaptive Biotechnologies

Adaptive Biotechnologies Speaker:

Mohammad Hussaini, MD

Director of Molecular Hematopathology at Moffitt Cancer Center